Gastric Cancer Pipeline Insight, 2020

(Albany,US) Delveinsight has launched a new report on Gastric Cancer Pipeline Insight, 2020

Gastric Cancer Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Gastric Cancer market. A detailed picture of the Gastric Cancer pipeline landscape is provided, which includes the disease overview and Gastric Cancer treatment guidelines.

The assessment part of the report embraces in-depth Gastric Cancer commercial assessment and clinical assessment of the Gastric Cancer pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastric Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Gastric Cancer Pipeline
Gastric Cancer Pipeline

Click Here For Free Sample Page:- https://www.delveinsight.com/sample-request/gastric-cancer-pipeline-insight

Gastric Cancer Pipeline Development Activities

The report provides insights into:

  • All of the companies that are developing therapies for the treatment of Gastric Cancer with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Gastric Cancer treatment.
  • Gastric Cancer key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Gastric Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

Gastric Cancer Analytical Perspective by DelveInsight

  • In-depth Gastric Cancer Commercial Assessment of products 

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

  • Gastric Cancer Clinical Assessment of products 

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

  • The Gastric Cancer report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Gastric Cancer across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Gastric Cancer therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Gastric Cancer research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Gastric Cancer

 

KEY FACT FROM THE REPORT

  • Approximately 0.9% of men and women are diagnosed with Gastric Cancer at some point during their lifetime, based on 2014-2016 data.
  • The number of new cases of Gastric Cancer and deaths was 7.4/100,000 men and women/year, and 3.1/100,000 men and women/year, respectively. These rates are age-adjusted and based on cases and deaths in 2012–2016.
  • In 2016, an estimated 113,054 people were living with Gastric Cancer in the United States.

 

MAJOR KEY PLAYERS OF THE REPORT

  • Innovent Biologics
  • RemeGen Co.
  • Surface Oncology

 

NAME OF DRUGS COVERED IN THE REPORT

  • IBI308
  • RC48
  • SRF617

 

Table of content

1. Report Introduction

2. Gastric Cancer 

2.1. Overview

2.2. History

2.3. Gastric Cancer Symptoms

2.4. Causes

2.5. Pathophysiology

2.6. Gastric Cancer Diagnosis

2.6.1. Diagnostic Guidelines

3. Gastric Cancer Current Treatment Patterns

3.1. Gastric Cancer Treatment Guidelines

4. Gastric Cancer – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Gastric Cancer companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Gastric Cancer Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Gastric Cancer Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Gastric Cancer Late Stage Products (Phase-III)

7. Gastric Cancer Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Gastric Cancer Discontinued Products

13. Gastric Cancer Product Profiles

13.1. Drug Name: Company

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

14. Gastric Cancer Key Companies

15. Gastric Cancer Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products

16.2.1. Reasons for the discontinuation

17. Gastric Cancer Unmet Needs

18. Gastric Cancer Future Perspectives

19. Gastric Cancer Analyst Review  

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation

22. About Delveinsight

Related Reports

ABOUT DELVEINSIGHT 

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

CONTACT US:

Shruti Thakur
[email protected]
+91-9650213330
DelveInsight

Related posts